ANKHD1 and uterine corpus endometrial carcinoma: The transcript read-through variant ANKHD1-BP3 was shown to be highly expressed in uterine corpus endometrial carcinoma, with the knockdown of this transcript inhibiting cellular metastasis, invasion, apoptosis, and necrosis [37].